CA2323630A1 - Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides - Google Patents

Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides Download PDF

Info

Publication number
CA2323630A1
CA2323630A1 CA002323630A CA2323630A CA2323630A1 CA 2323630 A1 CA2323630 A1 CA 2323630A1 CA 002323630 A CA002323630 A CA 002323630A CA 2323630 A CA2323630 A CA 2323630A CA 2323630 A1 CA2323630 A1 CA 2323630A1
Authority
CA
Canada
Prior art keywords
bpi
lps
bactericidal
gram negative
endotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323630A
Other languages
English (en)
Inventor
Marian N. Marra
Randal W. Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Invitron Corporation
Marian N. Marra
Randal W. Scott
Incyte Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/468,696 external-priority patent/US5089274A/en
Application filed by Invitron Corporation, Marian N. Marra, Randal W. Scott, Incyte Pharmaceuticals, Inc. filed Critical Invitron Corporation
Publication of CA2323630A1 publication Critical patent/CA2323630A1/fr
Abandoned legal-status Critical Current

Links

CA002323630A 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides Abandoned CA2323630A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US310,842 1989-02-14
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US468,696 1990-01-22
CA002048619A CA2048619C (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002048619A Division CA2048619C (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides

Publications (1)

Publication Number Publication Date
CA2323630A1 true CA2323630A1 (fr) 1990-08-15

Family

ID=27168936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323630A Abandoned CA2323630A1 (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides

Country Status (1)

Country Link
CA (1) CA2323630A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179560A1 (fr) 2015-05-06 2016-11-10 The Procter & Gamble Company Détection de facteurs de virulence microbienne orale
US9964472B2 (en) 2016-06-29 2018-05-08 The Procter & Gamble Company Methods for sampling gingival metabolites

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179560A1 (fr) 2015-05-06 2016-11-10 The Procter & Gamble Company Détection de facteurs de virulence microbienne orale
US9970934B2 (en) 2015-05-06 2018-05-15 The Procter & Gamble Company Detection of oral microbial virulence factors
US10156566B2 (en) 2015-05-06 2018-12-18 The Procter & Gamble Company Detoxification of microbial virulence factors in oral cavity
US10267797B2 (en) 2015-05-06 2019-04-23 The Procter & Gamble Company Detection of oral microbial virulence factors
US9964472B2 (en) 2016-06-29 2018-05-08 The Procter & Gamble Company Methods for sampling gingival metabolites

Similar Documents

Publication Publication Date Title
CA2048619C (fr) Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides
Marra et al. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity.
US5171739A (en) Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5334584A (en) Recombinant, non-glycosylated bpi protein and uses thereof
US5308834A (en) Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
Ooi et al. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.
Marra et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin.
US6222021B1 (en) Fragments of endotoxin binding protein and uses thereof
CA2119262C (fr) Composition contenant une proteine bactericide/permeabilisante et un porteur lipidique, methode de fabrication et utilisation
Shamova et al. Purification and properties of proline-rich antimicrobial peptides from sheep and goat leukocytes
Weinrauch et al. Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate.
EP0988314A1 (fr) Nouveaux peptides synthetiques possedant des proprietes antimicrobiennes et de neutralisation d'endotoxines et permettant de lutter contre le syndrome de septicemie
JPH11503006A (ja) カチオン性ペプチドの製造方法
Hellman et al. Antiendotoxin strategies
CA2166488A1 (fr) Proteines glycosylees et non glycosylees, bactericides, augmentant la permeabilite; methodes d'obtention
EP0586573B1 (fr) Proteine de liaison et de neutralisation d'endotoxine et ses utilisations
US6265187B1 (en) Recombinant endotoxin-neutralizing proteins
Gray et al. Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils
CA2323630A1 (fr) Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides
US5489676A (en) Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
Ohno LPS binding proteins in granulocyte lysosomes
Gough Scott Comparison of structurally related peptides in their antimicrobial and anti-endotoxic activity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead